Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals

In England and Wales, the National Institute for Health and Clinical Excellence (NICE) has provided guidance [technology appraisals (TAs) 130, 186, 195, 198 and 225] on the use of biologic drugs for the treatment of RA. This is based on an analysis of efficacy, safety and cost-effectiveness, and has...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiely, Patrick D. W., Deighton, Chris, Dixey, Josh, Östör, Andrew J. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276292/
https://www.ncbi.nlm.nih.gov/pubmed/22039226
http://dx.doi.org/10.1093/rheumatology/ker321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276292/
https://www.ncbi.nlm.nih.gov/pubmed/22039226
http://dx.doi.org/10.1093/rheumatology/ker321

Ejemplares similares